Compare CNXN & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | AMLX |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1997 | 2021 |
| Metric | CNXN | AMLX |
|---|---|---|
| Price | $70.14 | $17.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $21.56 |
| AVG Volume (30 Days) | 139.6K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $104.57 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $54.97 | $5.98 |
| 52 Week High | $75.00 | $18.74 |
| Indicator | CNXN | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 70.97 |
| Support Level | $56.30 | $12.17 |
| Resistance Level | $75.00 | $18.61 |
| Average True Range (ATR) | 2.14 | 0.98 |
| MACD | -0.40 | 0.41 |
| Stochastic Oscillator | 30.49 | 77.45 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.